![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Temporal Order of Resistance Emergence for Lamivudine/Emtricitabine, Efavirenz, and Raltegravir in Treatment-Naïve Patients
|
|
|
Reported by Jules Levin
International HIV and Hepatitis Drug Resistance Workshop, June 8-12, 2010, Dubrovnik. Croatia
M Miller1, S Fransen2, W Huang2, M Markowitz3, J Lennox4, J Zhao1, P Sklar1, Randi Leavitt1, H Teppler1, B-Y Nguyen1, C Petropoulos2, D Hazuda1
1Merck & Co. Inc., West Point, PA. 2Monogram Biosciences, Inc., South San Francisco, CA. 3Aaron Diamond Research Center, The Rockefeller University, New York, New York. 4Emory University School of Medicine, Atlanta, Georgia.
![](../images/061010/image002.gif)
![](../images/061010/image004.gif)
![](../images/061010/image006.gif)
![](../images/061010/image008.gif)
![](../images/061010/image010.gif)
![](../images/061010/image012.gif)
![](../images/061010/image014.gif)
![](../images/061010/image016.gif)
![](../images/061010/image018.gif)
![](../images/061010/image020.gif)
![](../images/061010/image022.gif)
![](../images/061010/image024.gif)
![](../images/061010/image026.gif)
![](../images/061010/image028.gif)
![](../images/061010/image030.gif)
![](../images/061010/image032.gif)
![](../images/061010/image034.gif)
![](../images/061010/image036.gif)
![](../images/061010/image038.gif)
May be overestimated-1 untested intervening time point
May be overestimated-2 untested intervening time points
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|